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“One of the symptoms of an approaching nervous 
breakdown is the belief that one´s work is terribly important.” 
Bertrand Russell 
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Abstract 
 
Biomarker discovery and assessment for prediction of  
kidney response after 
177
Lu-octreotate therapy 
Emil Schüler 
Department of Radiation Physics, Institute of Clinical Sciences,  
Sahlgrenska Academy at University of Gothenburg, Sweden, 2014 
Patients suffering from neuroendocrine tumors are oftentimes presented with spread disease at the time of 
diagnosis. Therapy using somatostatin analogs is today the only potentially curative treatment option for 
these patients. However, the kidneys are the dose-limiting organs in this type of therapy and the biological 
impact from radiopharmaceutical treatment is not fully understood. Furthermore, considering the large 
inter-individual variations in renal absorbed dose and toxicity, biomarkers for radiation damage would be 
of great significance in this type of therapy. 
The aims of this project were to study the normal kidney tissue response in vivo in mice following 177Lu 
and 177Lu-octreotate administration, to identify potential biomarkers following 177Lu exposure and evaluate 
their dependencies of absorbed dose, dose-rate, and time after injection, and to correlate these results with 
functional and morphological effects. 
The injected activity ranged between 0.3 and 150 MBq following 177Lu/177Lu-octreotate administration and 
the biological effect was investigated between 15 minutes and one year after administration. 
Transcriptional and miRNA variations were studied using microarray analysis and protein expression was 
investigated using mass spectrometry. Correlations between the transcriptional and protein variations were 
performed with functional parameters, as determined by 99mTc-DTPA/99mTc-DMSA scintigraphy, and with 
the morphological effects following 177Lu-octreotate administration. 
The number of differentially regulated transcripts following 177Lu/177Lu-octreoate administration was 
dependent on absorbed dose, dose-rate, time after injection, and tissue (kidney cortex or medulla) 
investigated. No transcript was found to be differentially regulated at all exposure conditions. The most 
recurrently regulated genes were the Serpina10 gene in kidney cortex, and the Egr1, Pck1, and Hmgcs2 
genes in kidney medulla. Substantial differences in response were found between 177Lu-octreotate and 
177LuCl3. Concerning the miRNA and protein data, a high absorbed dose-specificity was found, with few 
miRNAs/proteins found recurrently regulated at most exposure conditions.  
The transcriptional analyses showed a strong and diverse transcriptional response and the functional 
analyses revealed clear negative effects on renal function, with enhanced negative effects with absorbed 
dose and time after administration. Several potentially useful biomarkers were detected at the 
transcriptional level, markers with potential applicability in early prediction of late renal injury after 
177Lu/177Lu-octreotate exposure.  
Keywords: PRRT, somatostatin, radionuclide therapy, 177Lu-octreotate, scintigraphy, renal function, 
toxicity, kidney response, transcriptional response, radiation biology, microarray, molecular biomarkers, 
ionizing radiation, miRNA, proteomics  
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Populärvetenskaplig sammanfattning 
 
De tre vanligaste behandlingsformerna för cancer är idag kirurgi, kemoterapi och extern strålbehandling. 
Trots att dessa metoder kontinuerligt har förbättrats så är behandlingen av spridd sjukdom (flera 
metastaser i annan del av kroppen än ursprungstumören) fortfarande den största utmaningen inom 
cancerterapi. Kirurgi och extern strålbehandling lämpar sig inte för behandling av spridd tumörsjukdom 
samtidigt som det idag är svårt att bota spridd sjukdom med kemoterapi.  
Radionuklidterapi är en metod som har använts sedan 1940-talet. Denna metod går ut på att man 
administrerar ett radioaktivt ämne som tas upp i kroppen och på så vis behandlar tumören inifrån. Den 
mest använda radionukliden inom radionuklidterapi är radioaktivt jod. Principen för behandlingen är att 
man utnyttjar sköldkörtelns förmåga att ta upp och lagra jod. Genom denna behandling kan man mycket 
effektivt behandla tumörer i sköldkörteln, men kan även användas vid andra sjukdomstillstånd såsom 
hypertyreos (överaktiv sköldkörtel) och struma (förstorad sköldkörtel).  
Behandling av tumörer med radionuklider är dock begränsad då där oftast inte finns specifika 
upptagsvägar i tumören för rena radioaktiva nuklider. En nyare metod inom radionuklidterapi är istället 
användningen av tumörsökande molekyler märkta med radionuklider, även kallade radioaktiva läkemedel. 
Fördelen med radioaktiva läkemedel är att de kan söka upp alla tumörer i kroppen och på så vis mycket 
effektivt behandla metastaserad sjukdom. I detta arbete har radionukliden 177Lu använts ibland tillsammans 
med den tumörsökande substansen octreotate. Octreotate binder till receptorer på tumörcellernas yta och 
lämpar sig bra för behandling av neuroendokrina tumörer då dessa ofta har flera sådana receptorer jämfört 
med andra vävnader och organ. 177Lu bundet till octreotate (177Lu-octreotate) har visat bra resultat i 
behandlingen av patienter med neuroendokrina tumörer. 
Nackdelen med denna metod är dock att det finns risk för att njurarna tar skada av behandlingen och det är 
ofta njurarna som begränsar hur mycket av det radioaktiva läkemedlet man kan ge. Vid denna typ av 
behandling vill man att tumören tar upp en stor andel av läkemedlet, och den del som tumören inte tar upp 
ska lämna kroppen snabbt för att inte orsaka biverkningar. Det mesta an det radioaktiva läkemedelet 
lämnar kroppen via njurarna och en del stannar kvar i njurarna och kan orsaka biverkningar. Ett stort 
problem är också att man inte vet den totala mängd av det radioaktiva läkemedlet (stråldos) som njurarna 
tål innan skada uppstår. Troligen tål njurarna mer än den mängd läkemedel man ger idag. Om man kan ge 
patienterna större mängd av det radioaktivta läkemedlet så bör fler patienter botas. Dessutom finns stora 
skillnader i känslighet för strålning mellan patienter, vilket innebär att deras njurar tål olika mycket av det 
radioaktiva läkemedlet.  
Målet med denna avhandling var att undersöka njurarnas effekter efter injektion av 177Lu-octreotate. 
Resultaten visar att de biologiska effekterna på njurarna är mycket beroende av mängden radioaktivt 
läkemedlet som vi ger, men även vid vilken tidpunkt efter injektion som vi undersöker. Biverkningarna på 
njurfunktionen efter denna typ av behandling kommer ofta sent, vilket betyder att det kan ta lång tid innan 
någon uppenbar skada kan urskiljas. Resultaten visar också att biverkningarna vid högre administrerad 
mängd både blir kraftigare och att de uppkommer tidigare efter behandlingen. Vi har även letat efter 
biologiska markörer, som vi hoppas kunna använda för att i ett tidigt skede förutsäga risken för att 
njurarna tar skada, för att på så vis kunna optimera behandlingen individuellt för varje patient. Ett antal 
markörer har undersökts och studierna visade att vissa av dessa eventuellt kan förutsäga njurens svar på 
behandlingen.   
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Background 
 
Peptide receptor radionuclide therapy 
Radiolabeled somatostatin (SST) analog-based therapy has become a novel 
approach for the treatment of somatostatin receptor (SSTR)-overexpressing 
neuroendocrine (NE) tumors. There are five different somatostatin receptor 
subtypes, SSTR1-5, all belonging to the G protein-coupled receptor family [1, 2]. 
Patients who are considered for peptide receptor radionuclide therapy (PRRT) with 
radiolabeled SST analogs include those with inoperable metastasized tumors, with 
high expression of SSTR. Since the introduction of somatostatin receptor 
scintigraphy using 
111
In-DTPA-octreotide (Octreoscan®, Mallinckrodt Medical, 
Petten, The Netherlands) in the late 1980´s, Ocreoscan has become the golden 
standard in staging of SSTR positive NE tumor disease [3-6]. Thanks to promising 
results, including high tumor-to-normal-tissue activity and dose ratios, clinical 
therapy studies using 
111
In-octreotide was later attempted with encouraging results 
with regard to clinical benefits and biochemical responses [3-5]. However, tumor 
shrinkage was rarely observed, due to the far from optimal therapeutic properties of 
111
In (high photon contribution and very low electron energies) [7, 8]. 
Through the development of somatostatin analogs with higher receptor affinity 
(DOTA-octreotide and DOTA-octreotate) labeled with therapeutic radionuclides 
(
90
Y: high energy electron emitter, and 
177
Lu: medium energy electron emitter), 
increased therapeutic efficacy was achieved [9]. With higher electron energies, the 
dependence of homogeneous SSTR expression, internalization, and proximity to the 
DNA was reduced, compared with 
111
In (Table 1). 
Successful results related to tumor regression, increased overall survival, and 
improved quality of life have been reported through the use of 
177
Lu-octreotate and 
90
Y-octreotide for patients with different types of NE tumors, with response rates of 
about 50% [10-14]. These results are superior compared with chemotherapy, which 
is often the only other treatment modality available for these patients, where 
response rates seldom reaches 20% [15-17].  
The side effects associated with PRRT can be categorized as direct and delayed 
effects of radiotoxicity. The direct effects include nausea, vomiting, abdominal pain, 
and mild hair loss [18, 19]. These reactions are often normalized after the end of 
therapy and are easily treated. Hematologic effects observed after treatment include 
decreased blood cell count, which are also regarded as acute effects, However, this  
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Table 1. Physical data for 111In, 177Lu, and 90Y [20]. Values in parenthesis represent yield. 
Radio-
nuclide 
Half-
life Beta [keV]* 
Conversion 
electron [keV] 
Auger 
electron [keV] 
Gamma 
[keV] 
Characteristic 
X-ray [keV] 
111In 2.8 d   145 (8%) 0.51 (191%) 171 (90%) 23 (24%) 
      219 (5%) 2.6 (67%) 245 (94%) 23.2 (44%) 
        3.2 (31%)   26.1 (4%) 
        3.6 (4%)   26.1 (8%) 
        19.2 (11%)   26.6 (2%) 
            22.3 (5%) 
177Lu 6.7 d 47 (12%) 48 (5%) 1.9 (19%) 113 (6%) 7.9 (1%) 
    111 (9%) 102 (3%) 6.3 (5%) 208 (11%) 9 (1%) 
    149 (79%) 103 (103) 8.1 (3%)   54.6 (2%) 
      111 (111%)     55.8 (3%) 
90Y 2.7 d 934 (100%)         
* Average energy           
 
condition is usually mild and transient, and blood transfusion is seldom needed [21, 
22]. The delayed side effects include toxicity of liver and kidneys. Liver toxicity is 
most often presented in patients with liver metastases, and the distinction between 
treatment effects and metastasis progression is challenging [13]. The major risk 
organ is instead the kidneys where primary clearance of the radiolabeled SST 
analogs occurs. Also, accumulation and retention occurs, which in a therapeutic 
setting can be dose limiting due to the relatively long effective half-life of the 
radiopharmaceutical in the renal tissues [23]. To provide optimal therapy and to 
minimize normal tissue toxicity, we need to have a better understanding of 
biological responses following exposure. 
 
Radiopharmaceuticals  
Several parameters, such as type of radiation emitted, range of the particle vs. tumor 
size, half-life, biokinetics, and the effect on SSTR expression are to be considered in 
the choice of radionuclide [7, 24]. The most used radionuclides in PRRT with 
somatostatin analogs are 
177
Lu (Ē(𝑒−)=147 keV) and 90Y (Ē(𝑒−)=934 keV) (Table 
1). The effect of particle range can have significant consequences on treatment 
efficiency. Depending on the distribution of the radiopharmaceutical in the tumor, 
smaller tumors might be more efficiently treated with radionuclides emitting lower 
electron energies compared with higher electron energies, due to the resulting higher 
absorbed fraction [25, 26]. Furthermore, the particle range will probably also have 
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an effect on normal kidney tissue response, where higher electron energies will 
allow for direct irradiation of the glomerulus, the most radiosensitive subunit of the 
kidney [27]. In addition, the choice of somatostatin analog and the type of 
radionuclide bound will also affect treatment efficiency. Studies on patients have 
shown that the tumor/kidney absorbed dose ratio is higher with 
111
In-DOTATOC 
compared to 
111
In-DOTATATE [28], while the opposite is observed for 
177
Lu- 
DOTATOC vs. 
177
Lu-DOTATATE [29]. 
Biodistribution / dosimetry  
The biodistribution of the radiopharmaceutical within the total body is of vital 
importance for treatment planning. The biodistribution of 
177
Lu-octreotate has to 
some extent been studied in patients undergoing treatment [30, 31]. However, the 
most detailed knowledge comes from animal studies.  
Uptake of radiolabeled somatostatin analogs in normal tissues is generally lower 
than in tumor tissue [30, 32-34]. The highest normal tissue uptake in patients takes 
place in the kidneys with a maximal kidney uptake of between 1 and 4 %IA [31, 34-
38]. Furthermore, large individual variation in uptake has been observed in the 
kidneys after 
177
Lu-octreotate administration, with absorbed dose per administered 
activity between 0.33 and 2.4 Gy/GBq (mean value 0.8 Gy/GBq) after infustion of 
basic amino acids [31]. In animal models, kidney uptake values of 2.2-7.7 %IA/g 
have been reported in neuroendocrine tumor bearing Balb/c nude mice 24h after 
injection of 
177
Lu-octreotate [39-42]. In C57BL/6N mice, uptake values of 3.8-9.1 
%IA/g have been reported with large variations with the amount of injected activity 
[43]. The generally higher uptake values in e.g. the kidneys could be due to several 
factors, including strain differences (where Balb/c mice are immunodeficient with 
lack of T-cell production) or other physiological effects that the tumor tissue might 
have on the systemic properties of the organism.  
The biodistribution after 
177
LuCl3 administration has not been as extensively studied. 
At 24h and 7 days after injection, uptake values of 3.7 and 1.8 %IA/g have been 
reported (3.4 MBq) [41].  
Dose limiting organs 
Normal tissues set the limit for the amount of activity that can be safely 
administered to a patient. In most types of therapy using radiopharmaceuticals, the 
bone marrow is regarded as the limiting organ, which has a tolerance dose of 2.5 Gy 
(TD5/5 – 5% injury probability within 5 years) and 4.5 Gy (TD50/5 – 50% injury 
probability within 5 years), defined for fractionated external radiation exposure 
(2Gy/fraction given 5d/w) [44]. In more recently developed therapies using 
177
Lu-
octreotate and 
90
Y-octreotide, the dose limiting organ beside the bone marrow is the 
kidneys, where excretion of the major part of the radionuclide occurs [37, 38]. The 
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renal tolerance dose according to external radiation therapy is 23 Gy (TD5/5) and 28 
Gy (TD50/5) [45]. However, due to lower and continuous exponentially decreasing 
dose rates, inhomogeneous dose distribution within the organs and body, and 
particles of varying ionization density in radionuclide therapy compared with 
external irradiation, significant differences in radiobiological effects will most 
probably arise [24, 27], and studies on patients and animals demonstrate possibly 
higher tolerance doses for kidneys when 
177
Lu-octreotate and 
90
Y-octreotide is 
administered [46, 47]. However, since there is still limited knowledge of the effects 
of radionuclide therapy on normal tissues, tolerance doses are difficult to define.  
Clinically, bone marrow toxicity (reduced leukocyte count) is often observed after 
177
Lu-octreotate administration, with subsequent recovery within two months [48]. 
In early 
90
Y-DOTATOC studies nephrotoxicity has been shown with renal function 
loss and end-stage renal disease [21, 27, 49, 50].  
 
Radiation biology 
While it is assumed that the genetic background of an organ or tissue has a major 
role in the response to radiation, the radiation effects on cells at the molecular level 
are still largely unknown. The genetic information for all developmental and 
functional processes in the cell is located in the DNA. The functional unit of the 
genetic information is the gene which is built up of nucleotides. Genes, i.e. the 
genetic information, are thereby transcribed to RNAs and then translated into 
proteins, the functional unit of all processes in an organism (Figure 1).  
The process of transcription occurs in the nucleus and is carried out by replicating 
DNA into complementary RNA sequences using transcription factors and the 
enzyme RNA polymerase II. The initiation and stop of the gene expression is 
regulated by specific sequences known as promoter and terminator regions. The 
resulting primary mRNA then consists of coding (exons) as well as non-coding 
(introns) sequences. Mature messenger RNA (mRNA) is produced through RNA 
capping, polyadenylation, and RNA splicing.  
The mRNA carries the genetic code from the DNA to the ribosomes for translation 
of the RNA into a protein. At the ribosomes, the mRNA molecule is read in groups 
of three nucleotides which correspond to a specific amino acid.  The transfer RNA 
(tRNA) carries the different amino acids to the ribosomes in the protein synthesis 
process, and neighboring amino acids bind to each other by a peptide bond between 
the carboxyl group and the amino group of the two amino acids. The protein will 
then undergo modifications before the active protein is produced.  
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Figure 1. Schematic illustration of the central dogma of the cell. The DNA is 
transcribed, the pre-mRNA is spliced, and mature mRNA is produced. The 
mature mRNA is then transported into the cytoplasm where translation occurs 
in the ribosomes. Image is in the public domain and was retrieved from 
http://en.wikipedia.org/wiki/Messenger_RNA on Nov 9, 2014. 
Epigenetics  
The human genome consists of 20,000-25,000 protein coding genes. However, only 
a small fraction of these genes are actively translated into proteins in a specific 
tissue. Furthermore,  protein expression differs between different organs and tissues 
due to both qualitative and quantitative effects in gene expression. This variation in 
gene expression without altering the DNA nucleotide sequence is called epigenetics 
and includes DNA methylation, chromatin remodeling, and various RNA mediated 
processes.  
The process of DNA methylation (addition of a methyl group to cytosine or adenine 
in the DNA) and repression of gene expression occurs by allowing normal hydrogen 
binding. This in turn may cause the DNA molecule to be inaccessible to 
transcription factors and thereby gene silencing. Effects on gene expression can also 
be affected by cromatin remodeling through histone deacetylation, which causes 
changes in the histone structure and results in an increased compaction of the DNA, 
blocking the possiblity for RNA polymerase to bind to the DNA, thereby inducing 
transcriptional silencing. The process of deacetylation of lysine in the histones will 
increase the positive charge of the side chains of the histones, thereby increasing the 
strength of binding to the negatively charged DNA.  
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Epigenetic regulation can also occur through RNA based mechanisms [51]. It is now 
well known that not all of the RNA is translated into proteins [52, 53]. Micro-RNAs 
(miRNA) is the most studied non-coding RNA, and their function include RNA 
silencing and post-transcriptional regulation of gene expression [54]. Similar to 
mRNA, miRNA is transcribed by RNA polymerase II and folds to a double stranded 
hairpin loop structure. Precursor-miRNA (pre-miRNA) is then produced via 
interaction with the protein DGCR8 and the enzyme Drosha and exported out of the 
nucleus in to the cytoplasm where the loop is cleaved by the enzyme Dicer, yielding 
a mature miRNA of about 22 nucleotides in length. The mature miRNA is then a 
part of the RNA-induced silencing complex (RISC) containing Dicer, the protein 
argonaute and many other associated proteins. The miRNA binds to mRNA, and 
upon imperfect binding, translation will be inhibited, while after perfect binding, the 
mRNA will be degraded through the RISC complex [51].  
Single miRNA may target several mRNAs, and several miRNAs may be specific for 
the same mRNA. The majority of human genes are regulated, either directly or 
indirectly, by miRNAs [55, 56]. It has also been found that miRNAs play an 
essential role in fundamental cellular processes including cell metabolism, cell 
differentiation, apoptosis, and cell signaling as well as in cancer differentiation [55-
58]. Recently, the role of miRNA in the response to ionizing radiation has been 
investigated, and miRNAs has been found to be important in the DNA damage 
response [59-62].  
Cellular responses 
Traditionally the DNA has been considered to be the principal target for biological 
effects of radiation, where bioloical effects might be induced either by direct actions 
of the radiation, with direct ionization of a target atom in DNA, or by indirect 
actions, where the radiation interacts with e.g. water to produce free radicals that 
react with DNA. A variety of DNA lesions may be produced, e.g. single-strand 
breaks (SSB), double-strand breaks (DSB), base damage, and DNA-DNA and DNA-
protein cross-links [24, 63]. Following radiation-induced DNA damage, complex 
cellular responses including DNA repair, cell cycle arrest, mitotic catastrophe, 
necrosis, and apoptosis are potentially induced [64, 65].   
However, the radiation biology paradigm should include more than the direct action 
of radiation on the DNA. The so called non-target effect, which includes effects that 
are not directly DNA damage-related, should also be considered, e.g. membrane-
mediated signaling, abscopal effects, bystander effects, genomic instability, adaptive 
response, hypersensitivity, and inverse dose-rate effects [63]. The observation and 
acceptance of these responses has fundamentally changed the view of radiation-
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induced responses, and that the observed effects are not only due to direct ionization 
or free radicals. 
The non-target effect can be described as biological responses similar to those of 
directly exposed cells, which occur in non-irradiated cells [24, 63]. Observed 
responses include DNA damage, epigenetic changes, carcinogenesis, cytotoxicity, 
and more [63, 66, 67]. The mechanisms underlying non-targeted effects are not fully 
understood, but emerging evidence suggest the involvement of cytokines, including 
TNFα and IL-8, as well as reactive oxygen species [68-70]. Also smaller molecules, 
such as nucleotides and peptides, may be involved through gap junctions. This direct 
cell-to-cell communication is hypothesized to be involved in the non-targeted effect 
of normal tissue, and studies of alpha-irradiated human fibroblasts with inhibited 
intercellular communication showed reduced induction of both p53 and CDKN1A 
levels, as well as reduced cell killing [71, 72]. However, in tumor tissue, gap 
junctions are generally down-regulated [63]. 
In vivo evidence of the non-targeted effect includes studies in mice, where a 
reduction in tumor growth rates have been observed after high dose exposures of 
non-cancerous tissues [73] and partial irradiation of rat lung also resulted in damage 
in non-irradiated lung tissue [74].  
 
Kidney toxicity 
Normal kidney function 
The primary function of the kidneys is to remove metabolic waste products from the 
body through filtration of the blood and excretion, as well as to regulate blood 
volume and composition, electrolytes, blood pH, and blood pressure [75, 76]. The 
kidneys receive blood from the renal arteries which branch directly from the 
abdominal aorta, allowing about 20% of the cardiac output to be transported directly 
to the kidneys.  
The functional unit of the kidneys is the nephron, which is responsible for the urine 
production by filtration, reabsorption, and tubular secretion (Figure 2). The nephron 
consists of the glomerulus, proximal tubule, loop of Henle, distal tubule, and the 
collecting ducts. Filtration of the blood takes place in the glomerulus where the 
plasma is filtered through the glomerular barrier, which consists of capillary 
endothelium (negatively charged surface, glycocalyx), basement membrane (net 
negative charge), and epithelium of the Bowman’s capsule. The epithelium of the 
Bowman´s capsule will only allow passage of molecules smaller than ~60 kDa, and 
together with the charge selectivity of the capillary endothelium and the basement 
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membrane, the passage through the glomerulus will depend on the size, charge, and 
shape of the molecule [77, 78].  
The filtrate (primary urine) then drains into the Bowman´s space. Reabsorption and 
secretion takes place in the proximal tubule, loop of Henle, and the distal tubule. 
The reabsorption process can be divided into active and passive transport, where 
active transportation takes place through Na
+
/K
+
 pumps, whereas passive 
transportation takes place through Na
+
 symporters, ion channels, and osmosis. 
Furthermore, different transporter proteins are located in the tubular cell membrane, 
responsible for reabsorption of e.g. peptides. In total, 99% of H2O, 100% of glucose, 
99.5% of Na
+
, and 50% of urea is reabsorbed. Furthermore, all proteins and peptides 
are reabsorbed by the proximal tubules and transferred into lysosomes and digested 
by proteolytic enzymes. The catabolic products are then either transferred back into 
the circulation or excreted. The primary secretion of urea, bile salts, metabolites, 
 
 
 
Figure 2. Schematic illustration of nephron in the cortex (lighter part) and 
medulla (darker part). Image is in the public domain and were retrieved from 
http://en.wikipedia.org/wiki/Nephron on Nov 9, 2014. 
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drugs, and creatinine takes place in the proximal tubule, whereas organic acids, K
+
, 
and H
+
 are primarily secreted in the distal tubule.  
Further functions of the kidneys include production and secretion of hormones, 
renin, erythropoietin, and vitamin D, important for cardiovascular, hematologic, and 
skeletal muscle homeostasis [76]. Renin is released during low blood flow or low 
Na
+
 concentration. This will lead to the production of angiotensin II, which will 
result in increased retention of salt and water. In cases of low blood oxygen, the 
kidneys will secrete erythropoietin. This hormone will stimulate red blood cell 
development in bone marrow. The conversion of vitamin D to its active form also 
takes place in the kidneys, and this hormone is among others included in calcium 
homeostasis [75].  
Renal handling of 177Lu-octreotate 
After 
177
Lu-octreotate administration, the majority of the radiolabeled peptide will 
go through glomerular filtration and be excreted into the primary urine. Then, a 
small fraction will be retained in the kidneys through reabsorption in the tubules 
from the primary urine [79]. Uptake of 
177
Lu in the kidneys is highly heterogeneous, 
where the highest accumulation in rats takes place in the cortex, whereas the outer 
medulla has a concentration at 24h of 50-60% of the cortical activity, with no uptake 
detected in the inner medulla or the renal pelvis. However, a study on mice showed 
differences in 
111
In uptake in the kidneys after 
111
In-octreotide of female and male 
mice , where male mice were comparable to rats while the highest uptake in female 
mice was found in the outer medulla with less uptake in the cortex [80]. In addition, 
uptake in the cortex is highly heterogeneous, where it has been found that the 
majority of the uptake takes place in the proximal tubules in both rodents and 
humans, while only very low amounts are detected in the distal tubules and the 
glomeruli [79, 81]. 
 
The uptake mechanisms of radiolabeled somatostatin analogs in the kidneys are not 
fully understood. However, animal model studies have indicated that receptor-
mediated endocytosis via the megalin-cubilin complex and SSTR are involved, as 
well as amino acid/oligopeptide transporters, pinocytosis, and passive diffusion [37, 
46, 79, 82]. The megalin-cubilin complex is a scavenger protein receptor with high 
expression in the proximal tubule and is involved in the reabsorption of hormones, 
drugs, toxins, enzymes, and other proteins [37, 83-85]. It is today considered the 
most important receptor involved in protein uptake in the proximal tubule. The 
megalin receptor has a negative charge, and thus high affinity for the positively 
charged somatostatin analogs in the primary urine [79]; this was confirmed by both 
in vivo and in vitro studies with 
111
In-octreotide/octreotate [80, 86]. In the case of 
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uptake in the lysosomes in the proximal tubular cells, the radionuclide can be 
retained due to intracellular binding to metal binding proteins [27, 37]. 
Animals as model 
The effects of radiation exposure in mammals are influenced by both individual 
genetic predisposition and radiation dose. It is clear that the genetic background 
underlying different effects and reactions is both polygenic (multiple genes interact) 
and heterogeneous (the effect of different genes can sometimes give the same end 
result). Consequently, it is particularly difficult to analyze and identify the optimal 
absorbed dose response underlying the development of human side effects and 
reactions related to cancer treatment, because people from a genetic point of view, 
are very diverse group in which each individual is also subjected to its own specific 
set of complex environmental factors. One way to reduce the influence of such 
factors that complicate the optimal absorbed dose response is the use of an animal 
model system. If isogenic animals are used under controlled conditions, influence 
from factors such as genetic heterogeneity and variable environmental factors can 
greatly be reduced. Results obtained in the study of the models can be easily 
translated to humans using the available information from comparative gene 
mapping between humans and the model.  
In the present thesis, mice were used as a model to investigate the temporal and 
absorbed dose related response of the kidneys after 
177
Lu-octreotate and 
177
LuCl3 
administration. Mouse is a suitable model to improve our understanding of the 
effects of radiation exposure in mammals. However, there are both discrepancies 
and similarities between man and mice and an understanding of these differences are 
important in the evaluation of these trials [38]. In the kidneys, the expression of all 
five SSTR subtypes has been found in both man and mice, while expression in rat 
kidney is limited to SSTR3 & 5 [87-91]. However, the importance of somatostatin 
receptor expression in the kidneys concerning renal uptake of radiolabeled 
somatostatin analogs is in question. In rats, co-infusion of unlabeled octreotide did 
not effectively block renal uptake [79], and in SSTR-2 knockout mice, no difference 
in biodistribution was found between these and normal mice [92]. Also in man, 
SSTR expression in the kidneys seems to be less important [93].  
In both rodents and humans, inhomogeneous activity distributions have been 
described in the kidneys [80, 81], as well as a similarity in uptake mechanisms, 
including the megalin/cubilin complexes in the proximal tubule cells [86, 94]. 
However, factors that differ substantially between the species is kidney size and the 
size of the nephrons [78]. 
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Kidney injury after radionuclide therapy 
Data on kidney toxicity after radionuclide therapy are limited. In external beam 
radiation therapy, observed radiation-induced nephropathy includes azotemina, 
hypertension, and anemia [95]. Furthermore, mesangiolysis, atrophy and 
tubulointerstitial scarring may be induced. Some of these effects can be reversible or 
progression can occur to chronic nephropathy. Chronic nephropathy is related to 
loss of kidney mass and function, which can develop up to many years after therapy 
[37, 95].  
In rats and nude mice, dose-dependent late damage of the proximal tubules has been 
observed after 
177
Lu-octreotate administration [47, 96, 97]. Furthermore, selective 
and dose-dependent morphological changes have been observed in the renal cortex 
after 35 to 58 Gy of 
177
Lu-octreotate. In patients, both acute and chronic 
nephropathy has been observed after administration of 
90
Y-labeled somatostatin 
analogs [21, 98]. However, more data are needed to fully understand the nature of 
the induced kidney injury and to predict tolerance doses for this type of therapy.   
 
Biomarkers 
The general definition of a biomarker is “a measurable indication of a specific 
biologic state that is relevant for a specific process” [99]. The ideal biomarker 
should originate from the damaged cells and display organ specificity. The dose-
response of the ideal biomarker should be directly dependent on the extent of 
damage, and the change in expression should be expressed early after insult. The 
turn-over rate should be quick in order to be able to follow the disease process and 
the measurement technique of choice should be quick and reliable [76, 100].  
Advances in basic biological understanding are vital for the development of 
biomarkers for clinical practice, and biomarker development concerning the renal 
effects after 
177
Lu-octreotate administration requires a detailed knowledge of the 
organ under investigation [101]. It is important to remember that after exposure to 
stressors, induced kidney injury is a result of the relationship between cell 
dysfunction, cell death, proliferation, inflammation, and recovery and biomarker 
dependency on these relationships needs to be understood [102].  
Renal function 
The glomerular filtration rate (GFR), which describes the quantity of glomerular 
filtrate formed in the nephrons of both kidneys per unit of time, is the most 
examined parameter in the assessment of renal function [75]. GFR, adjusted for 
body surface area, is 100-130 ml/min/1.73m
2
 in men and women, and after age 40, 
GFR decreases with age. Chronic renal dysfunction demonstrated by decreased GFR 
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is generally followed by altered electrolyte and volume balance, decreased red blood 
cell production, hypertension, and altered bone mineralization [75, 103].  
The routinely used endogenous marker for renal function is serum creatinine. 
Creatinine is produced through metabolic processes in the muscles and is freely 
filtered by the glomerulus without renal tubular reabsorption [75], and increased 
levels in serum is an indicator of reduced GFR. However, several drawbacks exist 
when using serum creatinine and studies have shown a lack of power for the 
identification of early renal injury and dysfunction [102]. Furthermore, GFR needs 
to be reduced up to 50% before a change in serum creatinine levels is detected [103-
105]. Serum creatinine also highly depends on muscle mass, age, sex, medications, 
and hydration status. Significant injury can thus exist with no change in serum 
creatinine levels due to renal reserve, enhanced tubular section, and other factors 
[102, 106, 107].  
A more robust endogenous marker of GFR may instead be serum cystatin C, which 
is independent of muscle mass, sex, and age [108]. The production of cystatin C 
takes place in all nucleated cells at a constant rate and is freely filtered by the 
glomeruli and reabsorbed and catabolized by the tubules. Increased level in serum is 
an indicator of reduction in GFR [108-110]. Cystatin C may be a more reliable 
marker of GFR than creatinine, especially in cases of mild reductions of GFR [111]. 
The lack of sensitive functional assessment methods of the kidney may, however, 
limit the possibility of early and effective prevention of functional loss. Therefore, 
GFR should not be considered as the sole method for assessment of kidney response 
following 
177
Lu-octreotate administration. Markers for renal injury and damage, 
specifically for tubules due to the high uptake of 
177
Lu-octreotate in this part of the 
kidneys, could potentially prove invaluable in the characterization and investigation 
of renal damage. 
Measurement of kidney injury 
A number of biomarkers have been proposed for kidney injury. Most notably are N-
acetyl-beta-(D)-glucosaminidase (NAG), neutrophil gelatinase associated lipocalin 
(NGAL), kidney injury molecule-1 (KIM-1), interleukin-18 (IL-18), and liver-type 
fatty acid binding protein (FABP) [75]. Furthermore, increased levels of β2- 
macroglobulin (B2M), α1-microglobulin (A1M), and retinol-binding protein (RBP) 
in urine are indicative of tubular damage [75, 112]. However, the use of single 
markers may not be sufficient given the complex response found after radiation 
exposure and the heterogeneity of response of various dysfunction conditions in the 
kidneys. Furthermore, many patients have systemic diseases, which complicate the 
development of biomarkers [113]. The use of multiple markers may be needed to 
monitor interplay between different potential mechanisms [102, 114].  
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Morphological changes 
Upon whole kidney irradiation, morphological changes can induce a reduction in 
renal function which will be both time- and absorbed dose-dependent. Both tubular 
and glomerular alterations will be induced in the early stages of radiation 
nephropathy. Concerning the effects on the glomeruli, segmentalization (injury to 
the glomerular capillaries and mesangium), as well as nuclear enlargement have 
been observed, while the tubular effects include tubulolysis and tubular atrophy 
[95].  
Following radiation exposure, an increase in cellular proliferation in both 
glomerulus and tubules has been observed, likely as a response to radiation induced 
cell death. Also pronounced changes in cell phenotype have been observed in 
irradiated kidney cells, which in part may be due to radiation-induced chronic and 
persistent oxidative stress [95]. 
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Aims 
 
The overall aim of this thesis was to study the normal kidney tissue response in vivo 
after 
177
Lu/
177
Lu-octreotate administration. The main objective was to investigate the 
biological response at the gene expression level and to identify and evaluate 
potential biomarkers.  
 
The specific aims of the separate studies included in this thesis were: 
 To investigate the effects of absorbed dose on the transcriptional response in 
kidney tissue in mice after 
177
Lu-octreotate administration (Paper I) 
 
 To investigate the effects of dose rate and time after injection on the 
transcriptional response in kidney tissue in mice after 
177
LuCl3 administration 
(Paper II) 
 
 To investigate the effects of absorbed dose at late time points on the 
transcriptional response and function of kidney tissue in mice after 
177
Lu-
octreotate administration (Paper III) 
 
 To investigate the effects of absorbed dose at late time points on the 
proteomic and functional response in renal cortical tissue after 
177
Lu-
octreotate administration (Paper IV) 
 
 To investigate the effects of absorbed dose on the miRNA response in renal 
cortical tissue after 
177
Lu-octreotate administration, and the influence of 
miRNA on the expression of target genes (Paper V)  
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Methodological aspects  
 
Radiopharmaceuticals 
177
Lu, in the form 
177
LuCl3, and the somatostatin analog DOTA-Tyr
3
-octreotate were 
acquired from I.D.B. Holland (I.D.B. Holland BV, Baarle-Nassau, Netherlands). 
Preparation and radiolabeling were conducted according to the manufacturer´s 
instructions. The fraction of peptide bound 
177
Lu was determined by instant thin 
layer chromatography with 0.1 M sodium citrate as the mobile phase, where a 
fraction > 99% was considered satisfactory. The 
177
Lu-octreotate stock solution was 
diluted with saline solution to the final activity concentrations. 
Preparation of 
99m
Tc-DTPA (diethylene-triaminepenta-acetate) and 
99m
Tc-DMSA 
(dimercaptosuccinic acid) was performed according to the instructions by the 
manufacturer (Covidien, Millington, Dublin, Ireland).  
Before and after administration, the activity in the syringes was measured with a 
well-type ionization chamber (CRC-15R; Capintec, IA, USA) to determine the 
injected activity in each animal.  
 
Animals 
The animal strains BALB/c nude mice and C57BL/6N mice were used in the present 
investigations. Both strains are inbred, and the BALB/c nude mice are 
immunodeficient and lack T-cell production. During the animal trials, the animals 
were kept under normal nutritional conditions with extra care not to induce 
unwanted stress to the animals. All injections were performed through the tail vein 
and the animals were killed through cardiac puncture under anesthesia. The kidneys 
were surgically removed and one kidney was flash frozen in liquid nitrogen and 
stored at -80
o
C until analysis. The other kidney was harvested for either activity 
concentration measurement (Paper I and II) or stored in formalin followed by 
histological analysis (Paper II, and III). All studies were approved by the Ethical 
Committee on Animal Experiments in Gothenburg, Sweden.  
 
Dosimetry 
The absorbed dose estimation to the kidneys was based on the Medical Internal 
Radiation Dose (MIRD) pamphlet 21 formalism [115]: 
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?̅?(𝑟𝑆, 𝑇𝐷) =
?̃?(𝑟𝑆, 𝑇𝐷) ∑ 𝐸𝑖𝑌𝑖𝜙(𝑟𝑇 ← 𝑟𝑆, 𝐸𝑖 , 𝑇𝐷)
 
𝑖
𝑀(𝑟𝑇 , 𝑇𝐷)
, 
where ?̃?(𝑟𝑆, 𝑇𝐷) is the time integrated activity in the source organ, 𝑟𝑆, during the 
time of interest, 𝑇𝐷. 𝐸𝑖 is the energy and 𝑌𝑖 is the yield of the radiation 𝑖. 𝜙(𝑟𝑇 ←
𝑟𝑆, 𝐸𝑖 , 𝑇𝐷) is the absorbed fraction in the target organ, 𝑟𝑇, and 𝑀(𝑟𝑇 , 𝑇𝐷) is the mass 
of the target tissue. In the calculations, 𝑟𝑆 and 𝑟𝑇 were considered the same. ∑ 𝐸𝑖𝑌𝑖
 
𝑖  
was approximated to 147 keV, only including emitted electrons. The value of the 
absorbed fraction was taken from the literature (𝜙(𝑟𝑇 ← 𝑟𝑆, 𝐸𝑖 , 𝑇𝐷)=0.93 [116]). 
?̃?(𝑟𝑆, 𝑇𝐷) was calculated using previously published biodistribution data [40, 41, 43] 
and activity concentration measurements of the kidneys in the individual studies. 
The absorbed dose was calculated to whole kidney.  
 
RNA extraction, analysis, and data processing (I, II, III, V) 
The flash-frozen kidneys were dissected into cortical and medullary tissues and 
homogenized using the Mikro-Dismembrator S ball mill (Sartorius Stedim Biotech, 
Aubagne Cedex, France). Total RNA was extracted using the RNeasy Lipid Tissue 
Mini Kit (Qiagen, Hilden, Germany), or the miRNeasy Mini Kit (Qiagen, Hilden, 
Germany), according to the manufacturer´s instructions. RNA Integrity Number 
(RIN) values were retrieved using RNA 6000 Nano LabChip Kit with Agilent 2100 
Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA) and samples with RIN 
values above 6.0 were accepted for further analysis.  
In Papers I-III, the extracted RNAs were processed at the Swegene Center for 
Integrative Biology at Lund University (SCIBLU). MouseRef-8 Whole-Genome 
Expression Beadchips (Illumina, San Diego, USA), containing 25,435 probes were 
used for hybridization. Image acquisition and subsequent analysis were performed 
with Illumina BeadArray Reader scanner and BeadScan 3.5.31.17122 image 
analysis software, respectively. Data preprocessing and quantile normalization of 
raw signal intensities were conducted through the use of the web-based BioArray 
Software Environment (BASE) system. Nexus Expression 2.0/3.0 (BioDiscovery, 
Hawthorne, USA) software was used for further analysis with log2-transformed, 
normalized expression values and a variance filter. 
In Paper V, the RNA samples were processed at the TATAA Biocenter 
(Gothenburg, Sweden) and hybridized on to the Mouse miRNA oligo chip 4plex, 
containing approximately 1,300 miRNAs (Toray Industries, Tokyo, Japan). The 
chips were scanned with the Gene Scanner 3000 (Toray Industries, Tokyo, Japan) 
using standard settings for mouse miRNA v.19. Further analysis was conducted 
through the use of GenEx (Multid Analyses AB, Gothenburg, Sweden).  
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Table 2. Categories of biological processes. Reprint from [117], with kind permission from 
Britta Langen. 
Category Biological processes that... 
DNA integrity 
 
Damage and repair …recognize damage or initiate or facilitate repair pathways 
Chromatin organization …maintain the structural integrity of DNA on the chromatin level 
Gene expression integrity 
 
Transcription …are involved in transcription or its regulation 
RNA processing …are involved in processing immature or mature RNA or its regulation 
Translation …are involved in translation or its regulation 
Cellular integrity 
 
Physico-chemical environment  …are associated with e.g. regulation of ion homeostasis  or transport 
Cytoskeleton & motility … establish or regulate cytoskeleton integrity, chemotaxis or cellular motility 
Extracellular matrix & CM 
…regulate biogenesis of the cellular membrane (CM), maintain the  
extracellular matrix, regulate cell adhesion, etc. 
Supramolecular maintenance 
…are involved in or regulate e.g. protein (re)folding, protein oligomerization or 
modification, general transport of molecules or vesicles, etc. 
General ...are valid for any of the above subcategories 
Cell cycle and differentiation 
 
Cell cycle regulation …are involved in e.g. cell growth, regulation of growth arrest, etc. 
Differentiation & aging …regulate e.g. cellular development, proliferation, or aging  
Apoptotic cell death …are involved in regulating pro-apoptotic  or anti-apoptotic pathways 
Cell death …in non-apoptotic cell death, e.g. cytolysis 
General ...are valid for any of the above subcategories 
Cell communication 
 
Intercellular signaling …facilitate communication between cells, e.g. synaptic or hormone signaling 
Signal transduction …regulate or effect signal transduction, e.g. signal processing within a cell 
Metabolism 
 
Proteins, amino acids 
…regulate or facilitate anabolic or catabolic processes for proteins or amino 
acids 
Lipids, fatty acids …regulate or facilitate anabolic or catabolic processes for lipids or fatty acids 
Carbohydrates …regulate or facilitate anabolic or catabolic processes for carbohydrates 
Signaling molecules …regulate or facilitate anabolic or catabolic processes for signaling molecules 
Nucleic acid-related …regulate or facilitate anabolic or catabolic processes for nucleic acid-related 
Other ...are part of metabolism but not associated with other specific subcategories 
General ...are valid for any of the specific subcategories 
Stress responses 
 
Oxidative stress response 
…respond to e.g. superoxide, hydrogen peroxide, or other reactive oxygen 
species 
Inflammatory response …regulate or facilitate pro-inflammatory or anti-inflammatory responses 
Immune response 
…regulate or facilitate e.g. the acute-phase response, responses to pathogens, 
phagocytosis, or concern immune-specific biosynthesis 
Other ...are part of stress responses but not associated with other specific subcategories 
Organismic regulation 
 
Behavior …regulate behavioral responses of the organism 
Ontogenesis …regulate or facilitate developmental processes on the organ or organism level 
Systemic regulation …are involved in organismic regulations with systemic relevance 
Reproduction …regulate or facilitate e.g. germ cell development, parturition, or pregnancy  
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To determine differentially expressed transcripts and to control the false discovery 
rate, the Benjamini-Hochberg method was used in paper I-III (26). A p-adjusted 
value of <0.01 and a fold change of at least 1.5 (up- or down-regulation) were 
considered statistically significant.  
Gene Ontology (GO) terms were used to determine affected biological processes 
from the differentially regulated gene sets. The biological processes were 
categorized based on the GO terms employing a p value cutoff of <0.05 and ancestor 
charts. Eight main categories with more than 30 subcategories were generated to 
account for the higher level cellular functions (Table 2).  
Further analysis, including pathway analysis, up-stream regulator analysis, and 
target gene analysis, was conducted using the IPA software (Ingenuity Systems, 
Redwood City, CA, USA). 
 
Protein extraction, analysis, and data processing (IV) 
The fresh frozen kidneys were dissected and the kidney cortex was homogenized 
using a FastPrep®-24 instrument (MP Biomedicals, OH, USA). Total protein 
concentration was determined with Pierce™ BCA Protein Assay (Thermo Fisher 
Scientific, Waltham, USA). Total protein (100 µg/sample) was diluted and trypsin 
digested. After centrifugation the filtrates were subjected to isobaric mass tagging 
reagent TMT® according to the manufacturer’s instructions (Thermo Fisher 
Scientific). The peptides were further purified by Strong Ion Exchange Spin 
columns (Thermo Fisher Scientific) according to the manufacturer’s guidelines. The 
samples were desalted using PepClean C18 spin columns (Thermo Fisher Scientific) 
according to the manufacturer’s guidelines. 
The samples were then analyzed on an Orbitrap Fusion Tribrid mass spectrometer 
interfaced to an Easy-nLC II (Thermo Fisher Scientific). Ions were injected into the 
mass spectrometer under a spray voltage of 1.6 kV in positive ion mode. MS scans 
was performed at 120 000 resolution and m/z range of 400-1600. MS raw data files 
for each TMT (Tandem Mass Tag Reagent) set were merged for relative 
quantification and identification using Proteome Discoverer version 1.4 (Thermo 
Fisher Scientific). 
 
Quantitative real-time PCR (qPCR) (I,II,V) 
In order to validate gene expression data identified by microarray analysis, several 
genes with significant differential expression were selected for qPCR analysis in 
Papers I and II. Predesigned TaqMan assays (Applied Biosystems, Carlsbad, CA, 
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USA) were used on cDNA synthesized from the same RNA extraction as the 
microarray experiments (SuperScript
TM
 III First-Strand Synthesis SuperMix, 
Invitrogen, Carlsbad, CA, USA). The standard curve method was used for 
quantification and the geometric mean of three endogenous controls was used for 
normalization of the samples. In Paper V, the samples were reversely transcribed 
using the Universal cDNA Synthesis Kit II (Exiqon, Vedbaek, Denmark) according 
to the manufacturer´s protocol. The Pearson correlation coefficient was used in all 
studies to calculate the correlation between the microarray and the QPCR methods.  
 
Western blotting (II) 
To investigate the effect of transcriptional regulation of Havcr1 and Lcn2 at the 
protein level, Western blotting was carried out. Fresh frozen tissue samples (renal 
cortical and medullary tissue) were suspended in Mammalian Cell Lysis Buffer 
including Benzonase® Nuclease and Protease Inhibitor Solution and homogenized 
using the Mikro-Dismembrator S ball mill (Sartorius Stedim Biotech, Aubagne 
Cedex, France). The samples were centrifuged and the supernatant was transferred 
into microcentrifuge tubes and immediately frozen and stored at -20
o
C.  
 
Extracts (100 µg) were resolved by SDS-PAGE on 4-12% Bis-Tris gels (Invitrogen, 
Carlsbad, CA, USA), and later transferred to nitrocellulose membranes. The 
HAVCR1 protein was detected using anti-TIM-1 (MAB 1817, R&D Systems, 
Minneapolis, MN, USA) and Rat IgG Horseradish Peroxidase-conjugated antibody 
(HAF005, R&D systems, Minneapolis, MN, USA). LCN2 was detected using anti-
LCN2 (PAB 9542, Abnova, Taipei city, Taiwan) and Rabbit IgG Horseradish 
Peroxidase-conjugated antibody (NA934V, Amersham, Piscataway, USA). Anti-
ACTB and Mouse IgG Horseradish Peroxidase-conjugated antibody was used for 
detection of beta-actin as loading control (NA931V, Amersham, Piscataway, USA). 
SuperSignal® West Femto Maximum Sensitivity Substrate (Thermo Scientific, 
Waltham, MA, USA) was used for detection and digitalized images were acquired 
using Fujifilm Luminescent Image Analyzer LAS-1000 (Fujifilm, Tokyo, Japan). 
 
Scintigraphy (III,IV) 
To investigate the kidney function after 
177
Lu-octreotate, dynamic and static 
scintigraphic images were obtained using a single headed gamma camera (ADACT 
210, ADAC Laboratories A/S, Aalborg, Denmark). The gamma camera was 
equipped with a medium energy parallel-hole collimator (256x256 image matrix), 
and images were acquired with a 20% energy window over the 140 keV photon 
peak of 
99m
Tc. Mice were i.v. injected with 
99m
Tc-DTPA followed by dynamic 
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scintigraphic acquisition. Two to three days after 
99m
Tc-DTPA scintigraphy, static 
images with 
99m
Tc-DMSA were obtained. Three hours after 
99m
Tc-DMSA injection, 
a static 3 min image was acquired. In all scintigraphic images, a syringe with known 
99m
Tc activity was also imaged as calibration. 
The ImageJ software was used for image processing [118]. A region-of-interest 
(ROI) was outlined for each kidney at 10% level of maximal pixel count in the ROI 
and total number of counts was collected from the ROI. In addition, the number of 
counts in whole body and in a ROI around the calibration syringe was collected 
from each image. In the case of accidental subcutaneous injection, the number of 
counts in a ROI around the position of injection was subtracted from the number of 
counts in whole body.  
 
Histology (II,III) 
To study morphological changes in the kidneys, tissue slices (2 µm thick) were 
acquired from the formalin fixed kidneys and stained with hematoxylin-eosin. 
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Results & Discussion 
 
During radionuclide therapy, normal tissue exposure is inevitable, and will limit the 
amount of activity that can safely be administered. Risk of normal tissue toxicity 
will thus limit treatment efficiency. In 
177
Lu-octreotate therapy, the kidneys are the 
main limiting organ for late toxicity, where active reabsorption and retention takes 
place. However, there are substantial differences in absorbed dose to the kidneys 
among individual patients who have undergone this therapy. Furthermore, the 
biological response will not be strictly dose-dependent, but tolerance and subsequent 
toxicity will also vary strongly between individuals [119]. A deeper knowledge 
about the biological effects following 
177
Lu-octreotate administration is of vital 
importance in order to optimize this type of therapy. In addition, biomarkers for 
kidney function and damage need to be defined in order to easily and effectively 
predict and evaluate kidney toxicity after 
177
Lu-octreotate administration.  
 
Effects on transcriptional level (I,II,III) 
The number of differentially regulated transcripts following 
177
Lu administration 
was found to be dependent on absorbed dose, dose-rate, time after injection, and 
kidney tissue type (Figure 3). At 24h after injection, the total number of uniquely 
regulated transcripts at all dose levels was 281 and 480 in kidney cortex and 
medulla, respectively (Paper I). Initially, an increase in the number of differentially 
regulated transcripts was found with absorbed dose. The highest number of 
regulated transcripts was found at 4.3 Gy (kidney cortex) and 1.3 Gy (medulla), with 
a subsequent decrease with absorbed dose. The number of regulated transcripts was 
also found to be dose-rate (Paper II) and time (Paper II and III) dependent. In 
general, higher dose-rates (0.23-16 mGy/min) induced more transcriptional 
regulation compared with lower dose-rates (0.028-0.11 mGy/min) in both kidney 
cortex and medulla. A general increase in the number of regulated transcripts was 
also found with time where higher numbers of regulated transcripts were found at 
later time points (12 vs. 4 months).  
The increased number of differentially regulated transcripts with dose-rate is 
hypothesized to depend on the radiation insult on the tissues. With lower dose-rate, 
the damage induced per time interval will be lower, potentially allowing the cell to 
repair while at the same time continue with its normal function. At higher dose-rate, 
the higher insult per time interval will instead induce a stronger cellular response 
with increased repair and protection and decreased normal metabolic function.  
 24 
 
 
Figure 3. Total number up- (positive numbers, green bars) and down-
regulated (negative numbers, red bars) transcripts in Paper I, II, and III.  
Similar arguments can also be applied to the observed absorbed dose dependence, 
where the number of differentially regulated transcripts generally increased with 
absorbed dose (Figure 3). It may be suggested that the strongest response is 
observed when the absorbed dose is high enough to impose severe cellular damage 
but low enough to allow repair. It has previously been shown in vitro that low 
dose/low dose-rate will display markedly different effects compared with the same 
dose delivered acutely [120]. It has also been suggested that low dose-rate exposure 
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leads to a decrease in activation of key molecules in the cell, e.g. ATM (ataxia-
telangiectasia mutated). ATM is a kinase that plays an important role in the 
detection of DNA damage and initiation of cell cycle arrest, which could potentially 
result in decreased activation of early DNA damage responses of exposed cells [121, 
122] The increased number of differentially regulated transcripts with time could 
instead be due to the physiological conditions within the kidney. It is known that 
radiation will affect the physiology of the exposed tissue, and the increase in number 
of differentially regulated transcripts with time may be due to cellular adaptations 
that occur to this new environment.  
In total, Papers I, II, and III represent 34 specific exposure conditions of kidney 
tissue. When comparing the differentially regulated transcripts between the studies, 
no transcripts were found which were recurrently regulated at all exposure 
conditions. The most recurrently regulated transcripts are presented in Table 3, 
where the Serpina10 gene in kidney cortex, and the Egr1, Pck1, and Hmgcs2 genes 
in kidney medulla were the most commonly observed (16 different exposure 
conditions). Three of the recurrently regulated transcripts were differentially 
regulated in both kidney cortex and medulla: Cdkn1a, Dbp, and Hmgcs2, which are 
involved in cell cycle progression, regulation of transcription, and metabolic 
processes, respectively.  
A frequently observed tendency among the recurrently regulated transcripts was the 
dependence of the type of injected substance and time after injection. For example, 
the Cdkn1a gene was differentially regulated at 1.3-13 Gy in Paper I and also 
recurrently at 4-12 months after 
177
Lu-octreotate administration in kidney cortex and 
medulla, while after 
177
LuCl3 administration the gene was only differentially 
regulated in kidney cortex after 10 Gy at 140 days after injection, and not at all in 
kidney medulla. Considering the expression of Serpina10 and Lcn2, these genes 
were recurrently differentially regulated at the different exposure times 3-168h for 
both 
177
LuCl3 and 
177
Lu-octreotate, while they were rarely differentially regulated at 
later time points. This shows the importance of studying the transcriptional response 
at multiple time points and also the difficulties in translating the results between 
absorbed doses, time points, and injected substance. 
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Table 3. Recurrently regulated genes in Papers I, II, and III found in more than 12 exposure 
conditions. Data for human homolog expression was retrieved from www.proteinatlas.org.  
 
 Kidney cortex 
    
Expression of human homolog in 
kidney 
Gene 
symbol 
Full name 
RNA 
expression 
(FPKM) 
Protein 
localization (score) 
glomeruli tubules 
Serpina10 Serpin peptidase inhibitor A10 0 ND medium 
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 66 ND medium 
Napsa napsin A aspartic peptidase 67 ND high 
Ccrn4l CCR4 carbon catabolite repression 4-like 4 N/A N/A 
Dbp D site of albumin promoter binding protein 13 ND low 
Cdkn1a cyclin-dependent kinase inhibitor 1A 18 ND ND 
Spink6 serine peptidase inhibitor, Kazal type 6 0 low low 
Havcr1 hepatitis A virus cellular receptor 1 3 N/A N/A 
Mep1b meprin A, beta 0 ND ND 
 
 Kidney medulla 
    
Expression of human homolog in 
kidney 
Gene 
symbol 
Full name 
RNA 
expression 
(FPKM) 
Protein 
localization (score) 
glomeruli tubules 
Egr1 early growth response 1 165 medium medium 
Pck1 phosphoenolpyruvate carboxykinase 1 490 ND high 
Hmgcs2 3-hydroxy-3-methylglutaryl-CoA synthase 2 66 ND medium 
Cdkn1a cyclin-dependent kinase inhibitor 1A 18 ND ND 
Cml3 camello-like 3 human homolog not available 
Dbp D site of albumin promoter binding protein 13 ND low 
Lcn2 lipocalin 2 10 ND ND 
Angptl4 angiopoietin-like 4 5 ND medium 
Socs2 suppressor of cytokine signaling 2 18 medium medium 
Cfd complement factor D 2 ND high 
Igf2 insulin-like growth factor 2 24 medium medium 
FPKM=Fragments per kilobase of exon per million fragments mapped 
N/A=Not available 
ND=Not detected 
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Affected biological processes 
From the differentially regulated gene sets, GO terms were used to determine 
affected biological processes (the biochemical reactions known to be regulated by 
the expression-affected genes). Generally, an increased association with stress 
response and a reduced association with metabolic processes were seen with 
increasing absorbed dose (Paper I). Concerning the dose-rate effect, the highest 
overall number of differentially regulated transcripts was associated to stress 
response, with the strongest association at the lowest dose-rate investigated (0.028 
mGy/min) (Paper II). This result could also indicate that radiation-induced 
activation of immune response may be time dependent and not a dose-rate effect. 
The group exposed to the lowest dose rate in this study was killed one week after 
irradiation, and it can be hypothesized that with higher absorbed doses, an earlier 
induction of immune response may occur.  
At longer time points, the association with stress response was reduced in a time 
dependent manner after exposure to 10 Gy 
177
Lu. However, the study of the long 
term effects on kidney tissue after 
177
Lu-octreotate administration revealed that the 
recurrently differentially regulated transcripts were primarily found to be down-
stream targets of different cytokines and transcription factors (Paper III). The most 
strongly associated up-stream regulators included Ifng and Tnf in kidney cortex, and 
Ifng, Il1B, and Nr3c1 in kidney medulla. The Ifng, Tnfa and Il1 genes have been 
shown to be involved in “danger” signaling following irradiation, with the purpose 
of orchestration of tissue repair [123]. However, these genes are also involved in cell 
cycle arrest, cell survival, DNA repair, and senescence, and may thus indicate high 
level integration between cell and tissue responses [123]. Also the Nfkb complex 
was found to be an up-stream regulator, one of the most frequently activated 
transcription factors by radiation exposure [123-125]. The transcription factor Egr1 
was recurrently regulated in both tissues in this work, and has previously been found 
to be frequently regulated after irradiation [123-125]. Taken together, radionuclide 
exposure of the kidneys induces a stress response which is persistent and measurable 
up to 12 months after initial insult.  
Differences in exposure conditions   
In this work, the transcriptional variations were studied using both 
177
LuCl3 and 
177
Lu-octreotate. In Paper I and II, the same absorbed dose was delivered during 
24h, but with 
177
Lu-octreotate and 
177
LuCl3, respectively. The observed response was 
markedly different. The number of regulated transcripts in kidney cortex was 83 and 
135 after 
177
Lu-octreotate and 
177
LuCl3 administration, respectively, while in kidney 
medulla the corresponding numbers were 147 and 99. Of the differentially regulated 
transcripts, 11 and 37 transcripts were differentially regulated in kidney cortex and 
medulla, respectively, after both 
177
Lu-octreotate and 
177
LuCl3 administration. 
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Although the same radionuclide has been used, the biodistribution within the body 
and organs are markedly different between the two molecules, which might explain 
some of these observed differences. In a comparison of the biodistribution between 
177
LuCl3 and 
177
Lu-octreotate in Balb/c nude mice the activity concentration in most 
organs was highest for 
177
LuCl3 [41]. These results may be due to the rapid and non-
specific accumulation of 
177
LuCl3 in the extra-cellular fluid in the tissues, together 
with differences in handling of the kidneys. Specifically for the kidneys, a higher 
accumulation of 
177
LuCl3 was found at 24h compared with 
177
Lu-octreotate (3.7 vs. 
2.2 %IA/g). Furthermore, a more homogenous absorbed dose can be assumed to be 
delivered after 
177
LuCl3 due to non-specific distribution. However, the difference in 
response is not assumed to be due to the somatostatin analog itself. We have 
previously found that only minor transcriptional variations are induced in the 
kidneys 24h after administration of octreotate (data not shown). Therefore, the 
difference in response is assumed to be caused by differences in the irradiation 
parameters, and not by the somatostatin analog. However, a combination of effects 
in the biological response to the conjugate cannot be excluded.  
 
Protein expression (IV) 
The number of differentially regulated proteins in renal cortical tissue varied with 
time after injection and absorbed dose (Paper IV). No proteins were found to be 
recurrently regulated at all exposure conditions, and only three proteins (LRPPRC, 
PCK1, and RANBP1) were found differentially regulated at three exposure 
conditions, indicating that the affected proteins were primarily specific for the 
injected amount and time studied. Highest association among the affected proteins 
was found for RAN signaling, including oxidative phosphorylation, mitochondrial 
dysfunction, and valine degradation.  
A comprehensive review of radiation responsive proteins have previously been 
performed by Marchetti et al [126], where 261 genes with altered protein expression 
were listed. Of these, only 29 have been observed in vivo, indicating the low 
correlation between in vivo and in vitro studies. In Paper IV, out of the 128 uniquely 
regulated proteins, 24 have previously been identified as responsive to ionizing 
radiation. In addition to the differences in response between in vivo and in vitro 
settings, this low correlation could also be due to tissue specific regulation as well as 
divergent responses between radiopharmaceutical and pure radiation exposure.  
The correlation between the transcriptional data (Paper I, II, and III) and the protein 
data (Paper IV) was in general low. Regulated transcripts corresponding to the 
MEP1B, PCK1, SLC12A1, HSPA8, MIOX, DCN, ETHE1, FGG, AASS, BDH1, 
EHHADH, MYH11, S100G, ACY1, CYCS, DMGDH, HNRNPA2B1, IDH2, 
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LGMN, SLC4A1, ST13, and TGM1 proteins were, however, detected when 
comparing the entire data sets. No altered protein expression levels were found for 
the Cdkn1a, Dbp, Lcn2, and Per2 genes that were previously found recurrently 
regulated at the transcriptional level. The reason for this large deviation in results is 
surprising but it is known that the transcriptional and the protein expression do not 
always correlate [127]. Translation of an mRNA molecule to a functional protein 
takes place in several steps, including post-transcriptional and post-translational 
events causing deviations between the transcript and protein levels. Other potential 
reasons for the lack of protein expression of our previously proposed candidate 
biomarkers for 
177
Lu-octreotate exposure include potential rapid degradation of the 
produced protein and/or fast excretion from the kidneys to urine or reabsorption to 
the blood. Therefore, further studies using plasma and urine samples need to be 
conducted in order to identify novel biomarkers and evaluate the role of the 
previously reported candidate biomarkers. 
 
miRNA regulation (V) 
The role of miRNA in the response to ionizing radiation has recently been explored 
[61, 128], and several miRNAs have been identified as recurrently regulated 
following ionizing radiation exposure [59, 60, 62]. In Paper V, the miRNA response 
following different amounts of injected 
177
Lu-octreotate 24h after administration 
was investigated. In total, 57 unique miRNAs were identified as differentially 
regulated, with up-regulation as the primary mode of regulation. The most 
recurrently regulated miRNAs (regulation at four of five exposure conditions) were 
miR-194-5p, miR-107-3p, miR-3090-5p, and miR-3077-5p (Figure 4).  
The impact of miRNA regulation on mRNA transcriptional patterns was studied 
through a target gene analysis, where the miRNA data was analyzed in conjunction 
with the mRNA data obtained in Paper I. The target prediction analysis revealed a 
strong association with immune response pathways, with highest association with 
antigen presentation pathway and interferon signaling. The predicted upstream 
regulators corresponded well with the pathways affected, with IFNG inhibition and 
TP53 and TP73 activation.  
The majority of the miRNAs that were differentially regulated in Paper V have also 
previously been observed after radiation exposure. For example, the let-7 miRNA 
family were regulated at 0.05-19 Gy in a variety of cell lines and time points (0.5-
168h) after photon radiation, and is involved in cell proliferation, differentiation, 
and inhibition of the RAS pathway [61, 129-132]. The miR-10 family is involved in 
DNA damage response [133] and radioprotective/radiosensitizing effects [62, 134] 
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and the miR-15 family is involved in apoptosis and cell cycle control through 
targeting of the BCL2 and E2F1 proteins [135, 136]. 
 
 
Figure 4. The distribution of differentially regulated miRNAs in mouse 
kidney cortex 24h after 177Lu-octreotate administration. The 0.13 Gy dose 
level did not share any regulated miRNAs with the other dose levels. The 
target genes and associated biological function of the four miRNAs that were 
differentially regulated at four dose levels are shown to the right.  
 
Systemic response 
The radiation response within specific organs is complex due to the heterogeneity of 
cell types, where each cell type is subjected to its own specific and complex gene 
expression. Furthermore, a consequence of radionuclide administration is that all 
organs and tissues in the body are exposed to various amounts of ionizing radiation 
emitted by the radionuclide with resulting whole body systemic effects, which 
complicates the analysis of specific organs. Therefore, the detected responses in 
kidney tissue may be understood as not only a single consequence of kidney 
irradiation, but also an effect of communication between different cells, tissues and 
organs. Thus, systemic effects must also be considered when evaluating the 
biological response [137]. In addition, the biological effect will also be dependent 
on spatial, temporal, and tissue factors, which further complicates the observed 
response [138]. It is clear that low-dose/low dose-rate irradiation will display 
markedly different effects compared with the same dose delivered acutely. Previous 
studies have shown an increase in effectiveness of cell killing when low dose-rate 
irradiation was employed, compared with high dose-rate exposure, under certain 
conditions [120]. Also, induction of radio-resistance and radio-adaptation has been 
reported in normal cells [120]. 
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Potential biomarkers 
The biological response observed after radiation exposure is a relationship between 
cell dysfunction, cell death, proliferation, inflammation, and recovery. In the pursuit 
of novel biomarkers, these relationships need to be considered and a basic biological 
understanding and a detailed knowledge of the disease/injury under investigation is 
vital. The ideal biomarker should originate from the damaged cells and display 
organ specificity. The dose-response relationship of the biomarker should be directly 
dependent on the extent of functional damage, and the change in expression should 
be expressed early after exposure and measurable in easily available tissue/fluid 
sample. The turn-over rate of the biomarker molecule should be fast in order to be 
able to follow the disease process and the measurement technique of choice should 
be easy and reliable [100]. 
The search for biomarkers after radiation exposure has primarily been studied in 
vitro. However, systemic responses, heterogeneous and varying absorbed dose 
distribution in radionuclide therapy, and heterogeneity in cell types within tissues 
and organs make it hard to translate in vitro response to in vivo situation. Indeed, 
preclinical work on cell lines often fails to translate to the clinic [139]. Molecular 
features may be lost in the adaptation to culture conditions [140]. Gene expression 
profiles have been suggested as potential biomarkers for biodosimetry, primarily in 
vitro and ex vivo, and 97 genes have been proposed as markers for radiation [141-
143]. Recurrently observed genes include Gadd45, Cdkn1a, Mdm2, Mapk, Pcna, 
and Ddb2. Also potential protein biomarkers for radiation exposure has been 
studied, and the top candidates include ATM, H2AX, CDKN1A, and TP53 [126]. 
However, with the exception of Cdkn1a, these genes are rarely regulated in our data 
sets. Considering kidney damage, few studies have investigated the kidney response 
following exposure to ionizing radiation. However, extensive studies have been 
performed following chemically induced kidney injury in the search for biomarkers. 
The most prominent findings include Lcn2 (NGAL), Havcr1 (KIM-1), and Il-18 
[144-147]. These potential markers are all expressed in the proximal tubules, and 
also other cell types, and proposed as early indicators of acute kidney injury. 
However, their applicability as markers for chronic kidney damage is still to be 
determined.  
In the transcriptional data presented in this thesis, expression levels for the Havcr1, 
Lcn2, and Cdkn1a genes were generally the most prominent after 
177
Lu-octreotate 
administration (Figure 5). The Havcr1 gene, also known as KIM-1 (kidney injury 
molecule 1), has previously been used in preclinical studies as a predictor of kidney 
tubular damage in a variety of animals, and in humans [144, 145]. These studies 
have shown that Kim-1 mRNA levels are elevated after tubular damage, as well as at 
the protein level. In the present studies, the Havcr1 gene was significantly regulated  
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Figure 5. The transcriptional variations of Havcr1, Lcn2, and Cdkn1a as 
observed in Paper I, II, and III. Only statistically significant regulation is shown.  
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at all absorbed doses in Paper I and at all dose-rates in Paper II in kidney cortex 
while at longer time points this gene was rarely regulated (Paper II and III). Also the 
expression of Lcn2 gene (NGAL) has been suggested as a predictor of tubular injury 
and other studies have shown that the NGAL gene expression was up-regulated 
within a few hours of harmful injury and was among the earliest genes induced after 
injury where the NGAL protein was detected in both blood and urine [147, 148]. 
The Lcn2 gene was significantly regulated at all absorbed doses in Paper I and at all 
dose-rates in Paper II in kidney medulla. No regulation was observed at longer time 
points after 
177
LuCl3 exposure. However, after 
177
Lu-octreotate, this gene was 
recurrently regulated, especially at higher absorbed doses at 8 and 12 months after 
injection. Commonly for both these genes are that they have primarily been studied 
after acute kidney injury, and that their expression has been found to be strongly up-
regulated [144, 145, 147, 148]. The last finding is in contrast to the results presented 
in this thesis, where these genes were found down-regulated at the early time points 
investigated. Only at longer time points were these genes found to be up-regulated. 
The reason for this deviation is unknown, but could be due to that in the previous 
studies, the kidney injury was chemically induced and significant damage was 
present before measurements, while in the present studies, the gene expression levels 
were measured as early as 3h after injection, when probably no kidney damage was 
yet induced. 
The Cdkn1a gene is a cyclin dependent kinase inhibitor highly involved in cell cycle 
progression and has previously been seen to be consistently regulated in response to 
ionizing radiation [141-143]. The Cdkn1a gene has also been found to be up-
regulated shortly after acute renal failure [148]. While the gene was only statistically 
significantly regulated after 10 Gy at 140d after injection of 
177
LuCl3, it was 
recurrently regulated after 
177
Lu-octreotate administration in a dose-dependent 
manner independent of time point investigated (Figure 5) [149, 150].  
Identifying biomarkers for kidney toxicity and the ability to observe this change in 
expression at early time points is of highest concern to optimize individualized 
patient treatment. Other genes were also identified which showed significant de-
regulation at both early and late time points. With the exception of Cdkn1a, the 
Car3, Dbp, Hmgcs2, Mup2, Per2, S100a6, and Upk1b genes in kidney cortex and 
Actb, Adipoq, Car3, Cfd, Ckb, Dbp, Hmgcs2, Nupr1, Per2, and Upk1b genes in 
kidney medulla were found to be differentially regulated at both 24h and either at 4, 
8, or 12 months after 
177
Lu-octreotate administration (Paper I and III). The Dbp and 
Hmgcs2 genes were differentially regulated at all the studied dose levels (0.13-13 
Gy) in both tissues in Paper I, and the Per2 gene was differentially regulated at 
absorbed doses between 0.34 and 13 Gy (Figure 6). In Paper III, the Dbp and Per2 
showed clear dose-response in both tissues, while Hmgcs2 was recurrently regulated  
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Figure 6. The transcriptional variations of Dbp, Hmgcs2, and Per2 as observed 
in Paper I, II, and III. Only statistically significant regulation is shown. 
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in both tissues and displayed clear dose response at 24h after injection.  The 
expression of these genes at both early and late time points may warrant their use to 
evaluate the response to effects on the renal tissues.  
The use of single markers may, however, not be sufficient given the complex 
radiation response and kidney heterogeneity of various dysfunction conditions. 
Furthermore, patients often have systemic diseases, which may complicate 
biomarker definition [113]. The use of multiple markers may be needed and may be 
more useful, since interplay between different pathways could be monitored [102]. 
Furthermore, the ability to measure the biomarker levels in easily obtained samples, 
such as plasma/serum or urine, would be advantageous from a clinical point-of-
view.  
 
Renal scintigraphy 
99mTc-DTPA scintigraphy 
The study of the relationship between biomarker expression and functional and 
morphological effects is important in order to identify an association between early 
indicators and late toxicity. 
99m
Tc-DTPA is used for the external measurement of 
glomerular filtration rate (GFR) in the clinic, exclusively cleared by glomerular 
filtration in the kidneys, without secretion or reabsorption [108, 151, 152]. Normally 
following the clearance of 
99m
Tc-DTPA there is a rapid uptake phase of 1-3 minutes 
followed by a slow excretion phase when the tracer passes to the bladder [151]. The 
slope of the uptake phase correlates well with the glomerular filtration rate but due 
to practical issues this (uptake) time-phase could only be measured in Paper IV, and 
the data in Paper III illustrate the excretion phase of 
99m
Tc-DTPA. The functional 
effects of the kidneys following 
177
Lu-octreotate administration, as measured 
through 
99m
Tc-DTPA scintigraphy, revealed a clear reduction in excretion of 
99m
Tc-
DTPA to the bladder. While no difference in filtration or excretion rate could be 
observed at 4 months after injection at any absorbed dose, at 8 months, an altered 
time-activity curve was observed for the group injected with 90 MBq, while the 150 
MBq group displayed accumulation of the radio-tracer with no emptying into the 
bladder. A further alteration of the time-activity curve was observed at 12 months 
for the 90 MBq group. The accumulation of the radio-tracer for the 90 MBq group at 
12 months is comparable to that observed for the 150 MBq group at 8 months, 
indicating a prolonged time until renal function loss with reduced absorbed dose. 
However, no effects on the time activity curves were observed for the group injected 
with 30 MBq at any time point. Furthermore, measurements of the 150 MBq group 
at 12 months were not possible due to the poor physical condition of these mice. In 
Paper IV, altered 
99m
Tc-DTPA time-activity curves after 
177
Lu-octreotate 
 36 
 
administration were obtained, with a generally increased 
99m
Tc activity in the 
kidneys after 
177
Lu administration. An absorbed dose-dependent delay in time until 
maximum intensity was found. However, no obvious dose-dependent alteration in 
the overall time-activity curve pattern was observed. The clear accumulation of 
99m
Tc-DTPA in the kidneys following high absorbed doses was only found for the 
fractionation group (4x15 MBq at 12 months) in Paper IV. 
A previous study on rats injected with 460 MBq 
177
Lu-octreotate 
111
In-DTPA 
scintigraphy at 100-120 days after administration showed reduced maximal uptake 
compared with controls, with almost total excretion at 20 min and stabilization at  
40 min after injection. This finding is in line with the results observed in the present 
study at 4 months, where the activity concentration in the kidneys was stabilized at 
time points > 20 min. To our knowledge, a rise in renal time-activity-curve has not 
previously been observed after 
177
Lu-octreotate administration. However, similar 
results have previously been shown with 
99m
Tc-DTPA scintigraphy in dogs with 
nephrolithiasis [153]. Nevertheless, there were no indications that the mice 
developed calculi in the kidneys or ureters after irradiation, and the effect observed 
in the present study is most likely due to obstruction due to cell death.   
99mTc-DMSA scintigraphy 
99m
Tc-DMSA scintigraphic images are used for morphological studies in the clinic, 
demonstrating anatomy, tumors, renal trauma and inflammation, and to study 
relative differences in uptake between left and right kidney to estimate the renal 
functional mass [151]. 
99m
Tc-DMSA scintigraphy has also successfully been used 
after 
177
Lu-octreotate administration to study renal function in rats [96, 154]. A 
dose-dependent decrease in 
99m
Tc-DMSA concentration in kidneys was observed at 
109-146 d after administration of 
177
Lu-octreotate (23, 9.9, and 1.4 %IA/g for 0, 
278, and 555 MBq, respectively), indicating severe tubular damage for the highest 
injected activity [96]. Furthermore, a shift in distribution of 
99m
Tc-DMSA was 
observed with increased accumulation in the outer medulla with increased injected 
activity of 
177
Lu-octreotate. Similar results were observed 90 d after therapy using 
460 MBq 
177
Lu-octreotate, with a significant reduction in renal 
99m
Tc-DMSA 
uptake. However, in paper III, no clear reduction could be observed at any time 
point or absorbed dose investigated, despite the functional aberration observed for 
99m
Tc-DTPA. Nevertheless, in Paper IV, a reduction in 
99m
Tc-DMSA uptake was 
observed in most groups but without a clear absorbed dose-response relationship.  
 
Histological evaluation 
Signs of kidney toxicity were observed through histological evaluation at the highest 
activity level investigated (150 MBq, 55 Gy) at 8 and 12 months after 
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administration. The observed effects were located to the glomeruli with observed 
sclerosing and segmentalization of the glomerular tuft. Signs of cell death were 
observed in the glomeruli at 12 months after administration in the form of nuclear 
fragmentation and segmental necrosis. Furthermore, indications of inflammation 
were seen. The results are in contrast to previously published morphological effects 
of 
177
Lu-octreotate in rats (46-92 Gy, 4.5 months after injection) and nude mice (35-
58 Gy, 6 months after injection) [47, 96], where the primary changes were located in 
the proximal and distal tubules. Those changes included inhomogeneous nuclei, 
apoptosis, and necrotic cells in the proximal and distal tubules in rat kidney and 
flattened epithelium, loss of brush border, dilation, and empty lumina in mouse 
kidney. No significant changes of the glomeruli were observed in these studies. 
Explanations for these differences in response are not obvious. Speculations may 
include divergences between animal strains, and differences in absorbed dose 
distribution within kidneys of different size, time after administration, and repair 
processes in kidney tissue.  
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Concluding remarks 
 
Radionuclide therapy using radiolabeled peptides has recently become clinically 
available for treatment of various tumor types. However, kidneys and bone marrow 
are the dose limiting tissues. For the kidneys, the exposure limits are based on the 
tolerance doses established from external beam radiation therapy, despite significant 
differences between the two modalities. It is hypothesized that the exposure limit for 
the kidneys in radionuclide therapy can be increased without exceeding tolerable 
nephrotoxicity, leading to higher patient cure rates. However, we lack knowledge in 
the underlying mechanisms of radiation-induced effects on kidney tissue, which 
would give us a better understanding of nephrotoxicity after exposure to 
radiopharmaceuticals.  
In this work, genome-wide transcriptional responses were integrated with functional 
and morphological data from kidney tissue after administration of 
177
Lu-octreotate 
and 
177
LuCl3 to better understand the radiobiological response, and to identify and 
evaluate potential novel biomarkers for radiation-induced kidney injury. 
Furthermore, the effects of 
177
Lu-octreotate on the renal cortical response were 
evaluated by protein and miRNA analysis. 
The main conclusions for the individual papers included in this thesis can be 
summarized as follows: 
Distinct differences in the transcriptional response were found 24h after 
administration of various amounts of 
177
Lu-octreotate (Paper I). Significant 
differences in affected biological processes was observed between higher and lower 
absorbed doses, with lower association with metabolism and higher association with 
stress response with increasing absorbed dose.  
 
The transcriptional response was found to be predominantly uniquely regulated at 
specific dose-rates following 
177
Lu administration, and generally more transcripts 
were regulated at higher dose-rates (Paper II). Concerning time after injection, the 
number of differentially regulated transcripts increased with time, but decreased 
with absorbed dose, and the strongest affected associated biological processes 
included metabolism and stress-response.  
 
At longer time points after 
177
Lu-octreotate administration, clear negative effects 
was observed on the kidneys after high absorbed dose exposure, as determined by 
functional analysis (
99m
Tc-DTPA) and histological evaluation (Paper III). In 
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addition, a strong transcriptional response was observed, with recurrent regulation of 
e.g. Cdkn1a, C3, Dbp, Lcn2, and Per2.  
 
The evaluation of the proteomic response at longer time points after 
177
Lu-octreotate 
administration on renal cortical tissue revealed a low number of proteins which were 
differentially regulated at multiple exposure conditions (Paper IV). The functional 
evaluation revealed altered time-activity curves following administration of 
99m
Tc-
DTPA, with increased time until maximum intensity with increasing absorbed dose, 
and a generally decreased accumulation of 
99m
Tc-DMSA following 
177
Lu-octreotate 
administration, but no clear dose-response relationship was observed.  
 
The miRNA response was in general dose-specific 24 h after 
177
Lu-octreotate 
administration (Paper V). Stress-response related pathways were strongly associated 
and recurrent regulation of miR-194-5p, miR-107-3p, miR-3090-5p, and miR-3077-
5p was observed. 
 
Altogether, the results from these studies demonstrate distinct differences in the 
biological response after different absorbed doses, dose rates, and time after 
injection. The number of differentially regulated transcripts was generally higher at 
higher dose rates as well as at later time points. Furthermore, a reduced number of 
regulated transcripts were observed with increasing absorbed dose after 
177
LuCl3 
administration; this effect was not observed after 
177
Lu-octreotate administration. 
When comparing the regulated transcripts between the studies, no transcripts were 
recurrently regulated at all exposure conditions. The most recurrently regulated 
transcripts were related to the Serpina10 gene in kidney cortex, and the Egr1, Pck1, 
and Hmgcs2 genes in kidney medulla. Three of these transcripts were regulated in 
both kidney cortex and medulla, i.e. Cdkn1a, Dbp, and Hmgcs2. Considering only 
177
Lu-octreotate exposure, the most recurrently regulated transcripts were connected 
to Cdkn1a, Dbp, C3, Lcn2 and Per2 genes. A frequently observed tendency among 
the recurrently regulated transcripts was the dependence of the type of injected 
substance and time after injection. Furthermore, a strong association with stress 
response-related transcripts was found, especially for higher absorbed doses. 
Interestingly, 
177
Lu-octreotate administration induced a stress response of the 
kidneys which is persistent and measurable at least up to 12 months. 
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Future perspectives 
 
The primary focus of this work was to increase our understanding of the kidney 
response to 
177
Lu-octreotate and to identify potential novel biomarkers for radiation 
induced injury. In future work, several aspects of the current work should be 
explored further.  
The biomarkers which are proposed in this work ought to be further tested in 
animals at the protein level in, e.g., plasma and urine in order to evaluate their 
potential for clinical usage. The protein biomarker levels need to be correlated with 
the functional and morphological effects of the kidneys.  
Clinical verification should then be performed, where the proposed biomarkers 
should be tested in patients receiving 
177
Lu-octreotate treatment. Measurements 
should be performed both on plasma and urine samples collected at various time-
points after treatment, and careful long term follow-up of these patients should be 
undertaken in order to correlate kidney function/injury with the biomarker levels in 
the collected samples. A better understanding of the functional parameters studied 
today is also needed. 
Studies must be conducted in order to more fully understand the different 
dependencies of dose (both concerning absorbed dose and amount of peptide 
administered), dose-rate, and time after administration. Also the influence of other 
factors, e.g. tumor burden and inflammation processes, should be investigated in 
relation to biomarker levels.  
A clear difference between 
177
Lu and 
177
Lu-octreotate exposure to the kidneys were 
found in the present investigation, and this effect should be further explored in 
animals in order to obtain a better understanding of the biological response. It is 
desirable to be able to separate the part of the response that is due to the exposure of 
ionizing radiation, and the part that is due to the hormone analog, but synergistic 
effects might also be present.  
There are still great uncertainties in the tolerance dose of normal tissues following 
PRRT, and the limits used today are defined for external radiation therapy. There are 
indications that the tolerance doses after PRRT are higher than for external radiation 
therapy, and studies should be designed to specifically test the tolerance doses 
following 
177
Lu-octreotate administration.  
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